TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03260803
Drug: Oligopin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oligopin ,150 mg ,once daily, 12 week
Study: NCT03260803
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo,150 mg ,once daily, 12 week
Study: NCT00715689
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose level 1; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
Study: NCT00715689
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose level 2; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
Study: NCT00715689
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose level 3; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
Study: NCT00715689
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose level 4; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
Study: NCT01711398
Drug: Drug
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00750451
Drug: low molecular weight heparin (enoxaparine sodium)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg/day subcutaneously in the luteal phase after IVF treatment
Study: NCT00750451
Drug: crinone 8% gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: routine luteal phase support with progesterone gel
Study: NCT01020214
Drug: Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg
Normalized name: hydrochlorothiazide / olmesartan medoxomil Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01020214
Drug: Benicar HCT® Tablets 40 mg/25 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03661996
Drug: CNTX-4975-05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteoarthritis (OA) intra-articular injection of CNTX-4975-05
Study: NCT03661996
Drug: Lidocaine without epinephrine
Normalized name: epinephrine / lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mL lidocaine intra-articular injection
Study: NCT01057030
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules, Oral, 0 mg, once daily, 14 days
Study: NCT03845023
Drug: AD036 Dose 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: AD036 Dose 1 oral capsule administered before sleep
Study: NCT03845023
Drug: AD036 Dose 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: AD036 Dose 2 oral capsule administered before sleep
Study: NCT03845023
Drug: AD036 Dose 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: AD036 Dose 3 oral capsule administered before sleep
Study: NCT03845023
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral capsule administered before sleep
Study: NCT01748123
Drug: Chlorthalidone
Normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial dose of 12.5mg daily Chlorthalidone (force titrated to 25mg at 4 weeks)
Study: NCT01182207
Drug: Drospirenone/Ethinyl Estradiol (Gianvi®)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/0.02 mg Tablets
Study: NCT04319614
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml of saline will be administered in the beginning of the procedure.
Study: NCT02918292
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide dose will be 14.5 mg/kg IV daily for 2 days (Day -6 to Day -5) prior to transplantation and 50 mg/kg IV daily for 2 days (Day +3 to Day +4) after transplantation.
Study: NCT04459221
Drug: Gardasil 9, 9-Valent Intramuscular Suspension
Normalized name: Gardasil 9, 9-valent intramuscular suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: access to HPV vaccination near the college in a health bus
Study: NCT00352378
Drug: Anthracycline, Cyclophosphamide, Docetaxel, Capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be randomized to receive regimen A (AC) and regimen B(TX),preoperatively as follows:~Regimen A (AC): Intravenous infusion of Adriamycin 60mg/m2 , over 30 min, onD1 and Intravenous infusion of cyclophosphamide 600 mg/m2 over 30 min on D1. Regimen B(TX): Intravenous infusion of Taxotere 75 mg/m2 over 1 hr, on D1, and Xeloda 1000mg/m2.p.o. BID x 14days on D1-D14
Study: NCT03269747
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 Placebo tablets in the morning
Study: NCT02020499
Drug: Somatuline Autogel® (lanreotide) 60, 90, 120 mg.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receiving treatment as prescribed by the investigator and according to current treatment recommendations and routine clinical practice, and in line with local regulations.
Study: NCT02161406
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg of Placebo
Study: NCT02450890
Drug: ORADUR® First, then Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORADUR®-Methylphenidate is available in three dosage forms (22mg, 33mg or 44mg). The optimal dose for each subject will be determined in the open-label titration period. After randomization, subjects will be subjected to the 4-week double-blind two-way cross-over treatment phase with 2 study periods (2 weeks of placebo and 2 weeks of ORADUR®-Methylphenidate oral capsule at the optimal dose, according to a pre-determined randomization schedule).
Study: NCT01656395
Drug: MK-1029
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-1029 10 mg, 30 mg or 150 mg oral tablets taken QD at bedtime, based on randomization.
Study: NCT01656395
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parts I-II: Participants will receive Placebo tablets QD
Study: NCT04166604
Drug: Trifluridine/Tipiracil
Normalized name: TRIFLURIDINE/TIPIRACIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: After morning and evening meal~Days 1 through 5: 35mg/m2 (twice daily)~Days 6 through 7: recovery~Days 8 through 12: 35mg/m2 (twice daily)~Day 13 through 28: recovery
Study: NCT03623932
Drug: immunosuppressor/TNFalpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Treatment : immunosuppressor/TNFalpha as in standard practice
Study: NCT01983462
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03991988
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in this arm will take a matched placebo pill daily
Study: NCT00671619
Drug: ESBA105
Approvals — FDA: no, EMA: no, PMDA: no
Description: eye drops
Study: NCT04541732
Drug: Muscle Relaxant
Normalized name: MUSCLE RELAXANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium : 0.5mg/Kg.
Study: NCT04541732
Drug: Maintenance of general anaesthesia
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sevoflurane 0.7-1.5 MAC in 40% oxygen
Study: NCT00684203
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets; matching placebo for SCH 530348 loading and maintenance doses for 59 days
Study: NCT01939561
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is tablets identically with the Lamotrigine tablets.
Study: NCT00399867
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02989571
Drug: Intravenous normal saline administered at 250ml/hr
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous normal saline administered at 250ml/hr
Study: NCT02989571
Drug: Intravenous normal saline administered at 125ml/hr
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous normal saline administered at 125ml/hr
Study: NCT02345044
Drug: CS-3150
Normalized name: MyoGesic-CS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02345044
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02466243
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part A: Once daily on Days 1-28, then twice daily on Days 29-84.~Part B: Placebo twice daily on Days 1 - 365 of the OLE.
Study: NCT00477464
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2000mg/m\^2 twice daily (14 days out of 21 days)
Study: NCT03647384
Drug: Gulingji capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients take 0.6g of Gulingji capsules, 2 hours before breakfast, served with light salt water once a day. Also an oral take of 19.2mg Ginko Biloba Extract mimetic three times a day. Treatment lasts for 24 weeks.
Study: NCT03647384
Drug: Ginko Biloba Extract tablet
Normalized name: Ginko biloba leaf oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients take 0.6g of Gulingji mimetic, 2 hours before breakfast, served with light salt water once a day. Also an oral take of 19.2mg Ginko Biloba Extract tablet three times a day. Treatment lasts for 24 weeks.
Study: NCT01917006
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (normal saline) injected into specified muscle per protocol on Day 1.
Study: NCT00624013
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg up to 100 mg daily for 6 months
Study: NCT02652195
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo intranasal administration, 3 puffs per nostril, delivered prior to scanning session.
Study: NCT00661544
Drug: Ascorbic Acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose Levels 1, 2, \& 3: 1000 mg IV Days -9 to -3.
Study: NCT02219685
Drug: LDV/SOF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90/400 mg FDC tablet administered orally once daily
Study: NCT02219685
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet administered orally once daily
Study: NCT00226993
Drug: CPG 7909
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03643497
Drug: anti-infective drugs
Normalized name: INVESTIGATIONAL ANTI-INFECTIVE DRUGS,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: According to the models of population pharmacokinetics, the investigators and want to correlate use of antibiotics with treatment effectiveness and safety in children
Study: NCT02217488
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00742820
Drug: Calcium Acetate Oral Solution 667 mg per 5 mL
Normalized name: calcium acetate
DrugBank: Calcium Phosphate (DB11348)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug: Calcium acetate oral solution 667 mg calcium acetate, USP per 5 mL (169 mg of elemental calcium per 5 mL); Dosage: 30 mL of calcium acetate oral solution; Dosage frequency: three times per day with meals; Duration: 3 days and the morning of day 4, in total ten doses
Study: NCT00742820
Drug: Calcium Acetate 667 mg GelCaps
Normalized name: calcium acetate 667 MG
DrugBank: Calcium Phosphate (DB11348)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug: PhosLo GelCaps (calcium acetate) 667 mg (169 mg of elemental calcium per gelcap); Dosage: 6 gelcaps; Dosage frequency: three times per day with meals; Duration: 3 days and the morning of day 4, in total ten doses.
Study: NCT02811016
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Inhalation at 7:00 a.m. and 7 p.m.
Study: NCT00067990
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment with continued follow-up for five years.
Study: NCT00002456
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04758728
Drug: Epinephrine Topical
Normalized name: EPINEPHrine topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of epinephrine/adrenaline solution 1:1000 topically
Study: NCT00727415
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All patients will receive six monthly courses of FCL schedule consisting of three days of Fludarabine and Cyclophosphamide administration (d1-d3) combined with 14 days of Lenalidomide administration (d1-d14).
Study: NCT00745771
Drug: Diractin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04198948
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered orally once daily for 5 days in one of the two treatment periods.
Study: NCT02647788
Drug: Acetaminophen/Ibuprofen
Normalized name: ACETAMINOPHEN/IBUPROFEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: After hand surgery, take Acetaminophen 650 mg/Ibuprofen 400 mg every 6 hours as needed for pain until postoperative clinic visit
Study: NCT02647788
Drug: Acetaminophen/Codeine
Normalized name: ACETAMINOPHEN/CODEINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: After hand surgery, take Acetaminophen 300mg/Codeine 30 mg every 6 hours as needed for pain until postoperative clinic visit
Study: NCT00651313
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo vaginal gel administered once daily for 4 days
Study: NCT02290340
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo intramuscularly.
Study: NCT02290340
Drug: MEDI8897 10 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single dose of MEDI8897 10 milligram (mg) intramuscularly.
Study: NCT02290340
Drug: MEDI8897 50 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single dose of MEDI8897 50 mg intramuscularly.
Study: NCT04758728
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of normal saline solution NaCl 0,9% topically
Study: NCT01795729
Drug: optimal medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy: aspirin and a P2Y12 inhibitor as indicated
Study: NCT02461927
Drug: Placebo (psychoactive placebo midazolam) + Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects in this arm will receive (1) intravenous psychoactive placebo midazolam (0.045 mg/kg) once a week for 4 weeks (a total of 4 infusions) and (2) intramuscular placebo once a month (a total of 2 injections).
Study: NCT03470545
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo oral capsule
Study: NCT01558323
Drug: LCQ908
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single oral dose of LCQ908
Study: NCT03672487
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar pill manufactured to mimic Benznidazole
Study: NCT01321723
Drug: PTH analog
Normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
Approvals — FDA: no, EMA: no, PMDA: no
Description: A recombinant 1-31 amino acid fragment of PTH.
Study: NCT01321723
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02561806
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT01657877
Drug: Calcium sodium phosphosilicate
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSP high percentage weight by weight
Study: NCT01657877
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: No CSP and no fluoride
Study: NCT04081389
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT04081389
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT04081389
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00484601
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04592016
Drug: Voltaren - Diclofenac sodium gel 1% (GSK, USA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application in dermal-sampling visit
Study: NCT04592016
Drug: Pennsaid 2 % Topical Solution (Horizon Therapeutics, USA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application in dermal-sampling visit
Study: NCT04592016
Drug: Diclofenac sodium gel 1% (Perrigo, USA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application in dermal-sampling visit
Study: NCT01710800
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01340040
Drug: MEDI-573
Normalized name: Medi-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI-573 will be administrated once 7 days in Cohort 1 and 2, and once every 21 days in Cohort 3 as a IV infusion as part of a 21-day treatment cycle.
Study: NCT03887169
Drug: Methionine
Normalized name: Methionine
DrugBank: Methionine (DB00134)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of methionine from D1 to D60
Study: NCT03887169
Drug: Vitamin B12, B9, B6, C supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: In case of hyperhomocysteinemia
Study: NCT04064294
Drug: Intravenous Infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous levodopa given 1.0 to 1.5 mg/kg/hr from 0930 - 1130 on a single visit day.
Study: NCT01294410
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline, Intravenous, 0mg, Once a week for the first two weeks and every other week thereafter, 7 Weeks
Study: NCT01294410
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline, Intravenous, 0 mg, Every other week, Up to 757 days
Study: NCT01013740
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine
Study: NCT01152476
Drug: remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: General anesthesia is maintained witn sevoflurane and remifentanil.
Study: NCT01152476
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia is maintained with only sevoflurane and with normal saline instead of remifentanil
Study: NCT01682746
Drug: Photofrin (porfimer sodium) & photodynamic therapy.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) Photofrin~This is a dose escalation study. Patients will receive Photofrin via an IV infusion approximately 24 hours prior to their tumor resection surgery and Photodynamic Therapy (PDT). Patients will be light sensitive immediately upon receiving the Photofrin and must observe photosensitivity \& light precautions for a minimum of 30 days after the infusion.~Photodynamic Therapy (PDT)~After tumor resection, an optical fiber will be placed in the approximate center of the surgical cavity. Intralipid will be infused into the open tumor cavity while PDT is performed. The Intralipid will diffuse the light and ensure uniform delivery. Photoactivation of Photofrin is controlled by the total light dose delivered over the treatment time.
Study: NCT04169997
Drug: IMP4927
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMP4297 tablet.The starting dose from 100mg QD
Study: NCT04169997
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebos tablet.The starting dose from 100mg QD
Study: NCT00820664
Drug: Comparator: Estrace 0.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg tablet taken once daily for 28 days
Study: NCT00820664
Drug: Comparator: Estrace 2 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg tablets taken once daily for 28 days.
Study: NCT00820664
Drug: Comparator: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 0 mg capsule taken once daily for 28 days
Study: NCT04295330
Drug: 0.9% normal saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the placebo group, the same volume of normal saline will be administered during anesthesia. The postoperative PCIA device will contain sufentanil 2 μg/kg, granisetron 12 mg diluted to 200 mL in 0.9% normal saline solution with a total volume of 200 ml.
Study: NCT00642629
Drug: STA 5326 mesylate
Normalized name: mesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: STA 5326 mesylate 100mg taken orally twice a day for 8 weeks with the option to continue at the same dose and frequency for an additional 4 weeks.
Study: NCT00642629
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo taken orally twice a day for 8 weeks with the option to continue at the same dose and frequency for an additional 4 weeks.
Study: NCT02838576
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of placebo for 12 weeks. Adherence will be monitored during periodical hospital visits in order to receive pills.
Study: NCT03000348
Drug: Cysteamine
Normalized name: Cysteamine
DrugBank: Cysteamine (DB00847)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Cysteamine Capsule
Study: NCT03000348
Drug: Placebo Oral Capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Oral Capsule
Study: NCT03444844
Drug: Ga-68 P16-093 PET/CT scan
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV injection followed by PET/CT scanning
Study: NCT00385853
Drug: PTK787/ZK 222584
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily for each 28-day cycle
Study: NCT01719588
Drug: No intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is an observational study. Prolonged release tapentadol hydrochloride will be administered as per the recommended doses approved in Philippines. The recommended oral starting dose is 50 mg, 100 mg, 150 mg, 200 mg, or 250 mg every 12 hours, with or without food depending on the initial pain intensity and thereafter, the dose will be adjusted to maintain adequate analgesia with acceptable tolerability. The dosing regimen will be individualized according to the severity of pain being treated, the previous treatment experience, and the ability to monitor patients.
Study: NCT00296010
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: cyclophosphamide 50 mg/day orally continuously for 16 weeks
Study: NCT00296010
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: methotrexate 2.5 mg twice a day orally on days 1 and 4 of every week for 16 weeks
Study: NCT00296010
Drug: pegylated liposomal doxorubicin hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caelyx (R) (Doxil (R)) 20 mg/m2 iv x 8 doses (delivered every 2 weeks)
Study: NCT01588990
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive capecitabine 1000 mg/m\^2 per oral (PO) twice daily on Days 1-14 of 3 weeks cycle during Phase A treatment.